ZA202209159B - Mtorc modulators and uses thereof - Google Patents

Mtorc modulators and uses thereof

Info

Publication number
ZA202209159B
ZA202209159B ZA2022/09159A ZA202209159A ZA202209159B ZA 202209159 B ZA202209159 B ZA 202209159B ZA 2022/09159 A ZA2022/09159 A ZA 2022/09159A ZA 202209159 A ZA202209159 A ZA 202209159A ZA 202209159 B ZA202209159 B ZA 202209159B
Authority
ZA
South Africa
Prior art keywords
mtorc
modulators
rapamycin
specificity
rapamycin analogs
Prior art date
Application number
ZA2022/09159A
Inventor
T Tzannis Stelios
J Massey Ian
Froidbise Alexandre
Eppe Guillaume
Original Assignee
Aeovian Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aeovian Pharmaceuticals Inc filed Critical Aeovian Pharmaceuticals Inc
Publication of ZA202209159B publication Critical patent/ZA202209159B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/18—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A61K38/063—Glutathione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Molecular Biology (AREA)
  • Obesity (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biochemistry (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Transplantation (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Saccharide Compounds (AREA)

Abstract

Novel rapamycin analogs and uses thereof are disclosed herein. The rapamycin analogs of the present disclosure show increased mTORC1 specificity and lowered mTORC2 specificity relative to rapamycin.
ZA2022/09159A 2019-01-22 2022-08-16 Mtorc modulators and uses thereof ZA202209159B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201962795482P 2019-01-22 2019-01-22

Publications (1)

Publication Number Publication Date
ZA202209159B true ZA202209159B (en) 2023-12-20

Family

ID=71737003

Family Applications (2)

Application Number Title Priority Date Filing Date
ZA2021/05847A ZA202105847B (en) 2019-01-22 2021-08-16 Mtroc modulators and uses thereof
ZA2022/09159A ZA202209159B (en) 2019-01-22 2022-08-16 Mtorc modulators and uses thereof

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ZA2021/05847A ZA202105847B (en) 2019-01-22 2021-08-16 Mtroc modulators and uses thereof

Country Status (14)

Country Link
US (4) US11230557B2 (en)
EP (2) EP3914245A4 (en)
JP (4) JP7061236B2 (en)
KR (2) KR20240033298A (en)
CN (3) CN116947884A (en)
AU (3) AU2020210921B2 (en)
BR (1) BR112021014479A2 (en)
CA (2) CA3236782A1 (en)
EA (1) EA202191983A1 (en)
GB (3) GB2586764B (en)
IL (1) IL285067A (en)
MX (2) MX2021008777A (en)
WO (1) WO2020154447A1 (en)
ZA (2) ZA202105847B (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11202012447YA (en) 2018-06-15 2021-01-28 Navitor Pharm Inc Rapamycin analogs and uses thereof
GB2586764B (en) 2019-01-22 2022-02-09 Aeovian Pharmaceuticals Inc MTORC modulators and uses thereof
IL293549A (en) * 2019-12-05 2022-08-01 Anakuria Therapeutics Inc Rapamycin analogs and uses thereof
EP4126229A4 (en) 2020-03-27 2024-04-17 Aeovian Pharmaceuticals, Inc. Mtorc1 modulators and uses thereof
WO2022020522A2 (en) * 2020-07-21 2022-01-27 Aeovian Pharmaceuticals, Inc. Mtorc1 modulators and uses thereof
WO2024068159A1 (en) * 2022-09-30 2024-04-04 Biotronik Ag Synthesis and characterization of cyclic hydrocarbon esters of everolimus

Family Cites Families (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4475196A (en) 1981-03-06 1984-10-02 Zor Clair G Instrument for locating faults in aircraft passenger reading light and attendant call control system
US4447233A (en) 1981-04-10 1984-05-08 Parker-Hannifin Corporation Medication infusion pump
US4439196A (en) 1982-03-18 1984-03-27 Merck & Co., Inc. Osmotic drug delivery system
US4447224A (en) 1982-09-20 1984-05-08 Infusaid Corporation Variable flow implantable infusion apparatus
US4487603A (en) 1982-11-26 1984-12-11 Cordis Corporation Implantable microinfusion pump system
US4486194A (en) 1983-06-08 1984-12-04 James Ferrara Therapeutic device for administering medicaments through the skin
US4596556A (en) 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
GB2189699A (en) 1986-04-30 1987-11-04 Haessle Ab Coated acid-labile medicaments
GB2189698A (en) 1986-04-30 1987-11-04 Haessle Ab Coated omeprazole tablets
US4790824A (en) 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
US4941880A (en) 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
CH677886A5 (en) 1989-06-26 1991-07-15 Hans Georg Prof Dr Weder
US5064413A (en) 1989-11-09 1991-11-12 Bioject, Inc. Needleless hypodermic injection device
US5312335A (en) 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
ZA935112B (en) * 1992-07-17 1994-02-08 Smithkline Beecham Corp Rapamycin derivatives
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
GB9221220D0 (en) * 1992-10-09 1992-11-25 Sandoz Ag Organic componds
ATE191218T1 (en) * 1993-12-17 2000-04-15 Novartis Ag RAPAMYCIN DERIVATIVES AS IMMUNOSUPPRESSORS
KR100477070B1 (en) 1994-03-25 2006-04-21 이소테크니카 인코포레이티드 Enhancing the efficacy of pharmaceuticals by deuteration
US6334997B1 (en) 1994-03-25 2002-01-01 Isotechnika, Inc. Method of using deuterated calcium channel blockers
ES2094688B1 (en) 1994-08-08 1997-08-01 Cusi Lab MANOEMULSION OF THE TYPE OF OIL IN WATER, USEFUL AS AN OPHTHALMIC VEHICLE AND PROCEDURE FOR ITS PREPARATION.
FR2730932B1 (en) 1995-02-27 1997-04-04 Oreal TRANSPARENT NANOEMULSION BASED ON FLUID NON-IONIC AMPHIPHILIC LIPIDS AND USE IN COSMETICS OR DERMOPHARMACY
FR2742676B1 (en) 1995-12-21 1998-02-06 Oreal TRANSPARENT NANOEMULSION BASED ON SILICON SURFACTANTS AND USE IN COSMETICS OR DERMOPHARMACY
EP2182067A3 (en) 1996-07-05 2010-07-14 Biotica Technology Limited Hybrid polyketide synthases
FR2755854B1 (en) 1996-11-15 1998-12-24 Oreal NANOEMULSION BASED ON NON-IONIC AND CATIONIC AMPHIPHILIC LIPIDS AND USES
FR2760970B1 (en) 1997-03-18 2000-03-10 Oreal NANOEMULSIONS BASED ON NON-IONIC AMPHIPHILIC LIPIDS AND AMINO SILICONES AND USES
FR2787027B1 (en) 1998-12-14 2001-01-12 Oreal NANOEMULSION BASED ON SUGAR FATTY ESTERS OR SUGAR FATHER ETHERS AND ITS USE IN THE COSMETIC, DERMATOLOGICAL AND / OR OPHTHALMOLOGICAL FIELDS
FR2787026B1 (en) 1998-12-14 2001-01-12 Oreal NANOEMULSION BASED ON MIXED ESTERS OF FATTY ACID OR FATTY ALCOHOL, CARBOXYLIC ACID AND GLYCERYL, AND ITS USES IN THE COSMETIC, DERMATOLOGICAL AND / OR OPHTHALMOLOGICAL FIELDS
FR2787326B1 (en) 1998-12-17 2001-01-26 Oreal NANOEMULSION BASED ON FATTY ESTERS OF GLYCEROL, AND ITS USES IN THE COSMETIC, DERMATOLOGICAL AND / OR OPHTHALMOLOGICAL FIELDS
FR2787325B1 (en) 1998-12-17 2001-01-26 Oreal NANOEMULSION BASED ON OXYETHYLENE OR NON-OXYETHYLENE SORBITAN FATTY ESTERS, AND ITS USES IN THE COSMETIC, DERMATOLOGICAL AND / OR OPHTHALMOLOGICAL FIELDS
FR2787728B1 (en) 1998-12-23 2001-01-26 Oreal NANOEMULSION BASED ON FATTY ESTERS OF PHOSPHORIC ACID, AND ITS USES IN THE COSMETIC, DERMATOLOGICAL, PHARMACEUTICAL AND / OR OPHTHALMOLOGICAL FIELDS
FR2787703B1 (en) 1998-12-29 2001-01-26 Oreal NANOEMULSION BASED ON ETHOXYL FATHER ETHERS OR ETHOXYL FATTY ESTERS, AND ITS USES IN THE COSMETIC, DERMATOLOGICAL AND / OR OPHTHALMOLOGICAL FIELDS
FR2788007B1 (en) 1999-01-05 2001-02-09 Oreal NANOEMULSION BASED ON BLOCK COPOLYMERS OF ETHYLENE OXIDE AND PROPYLENE OXIDE, AND ITS USES IN THE COSMETIC, DERMATOLOGICAL AND / OR OPHTHALMOLOGICAL FIELDS
FR2788449B1 (en) 1999-01-14 2001-02-16 Oreal NANOEMULSION BASED ON ALKYLETHER CITRATES, AND ITS USES IN THE COSMETIC, DERMATOLOGICAL, PHARMACEUTICAL AND / OR OPHTHALMOLOGICAL FIELDS
FR2789076B1 (en) 1999-02-02 2001-03-02 Synthelabo ALPHA-AZACYCLOMETHYL QUINOLEINE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION
AU783158B2 (en) 1999-08-24 2005-09-29 Ariad Pharmaceuticals, Inc. 28-epirapalogs
DK1278881T3 (en) 2000-04-13 2010-05-10 Biotica Tech Ltd Glycosylated hybrid products and their preparation and use
US6776796B2 (en) 2000-05-12 2004-08-17 Cordis Corportation Antiinflammatory drug and delivery device
FR2811564B1 (en) 2000-07-13 2002-12-27 Oreal NANOEMULSION CONTAINING NON-IONIC POLYMERS, AND ITS USES IN PARTICULAR IN THE COSMETIC, DERMATOLOGICAL, PHARMACEUTICAL AND / OR OPHTHALMOLOGICAL FIELDS
EP1425311A4 (en) 2001-01-11 2004-12-01 Eastman Chem Co Cyclodextrin sulfonates, guest inclusion complexes, methods of making the same and related materials
FR2819427B1 (en) 2001-01-18 2003-04-11 Oreal TRANSLUCENT NANOEMULSION, MANUFACTURING METHOD THEREOF AND USES THEREOF IN THE COSMETIC, DERMATOLOGICAL AND / OR OPHTHALMOLOGICAL FIELDS
EP2545937A1 (en) 2001-06-05 2013-01-16 The Regents Of The University Of Michigan Nanoemulsion vaccines
GB0128680D0 (en) 2001-11-29 2002-01-23 Biotica Tech Ltd Hybrid glycosylated products and their production and use
EP1655372A3 (en) 2002-07-16 2008-01-16 Biotica Technology Limited Production of polyketides and other natural products
US7476393B2 (en) 2002-11-29 2009-01-13 L'oreal Process for the preparation of a cationic nanoemulsion, and cosmetic composition
US7468402B2 (en) 2004-03-17 2008-12-23 Baker Hughes Incorporated Polymeric nanoemulsion as drag reducer for multiphase flow
EP1896075A2 (en) * 2005-06-22 2008-03-12 LifeCycle Pharma A/S Pharmaceutical compositions comprising tacrolimus and a cyp3a4 inhibitor
GB0601406D0 (en) 2006-01-24 2006-03-08 Novartis Ag Organic Compounds
US20110098241A1 (en) 2008-04-14 2011-04-28 Poniard Pharmaceuticals, Inc. Rapamycin analogs as anti-cancer agents
KR101563308B1 (en) 2008-11-11 2015-10-26 씨에스피씨 종콰이 팔마씨우티컬 테크놀로지 (스자좡) 컴퍼니 리미티드 Inclusion complexes of pinocembrin with cyclodextrin or its derivatives
CN102731527A (en) 2012-07-12 2012-10-17 浙江医药股份有限公司新昌制药厂 Synthesis method of sirolimus 42-ether derivative
WO2014153118A1 (en) 2013-03-14 2014-09-25 The Board Of Trustees Of The Leland Stanford Junior University Treatment of diseases and conditions associated with dysregulation of mammalian target of rapamycin complex 1 (mtorc1)
ES2857226T3 (en) 2014-03-15 2021-09-28 Novartis Ag Regulable chimeric antigen receptor
JP6692798B2 (en) * 2014-09-11 2020-05-13 ザ・リージエンツ・オブ・ザ・ユニバーシテイ・オブ・カリフオルニア mTORC1 inhibitor
CN104341434B (en) 2014-10-16 2016-04-06 福建省微生物研究所 The rapamycin triazole derivatives replaced and purposes
AU2016315653A1 (en) * 2015-08-28 2018-03-15 Buck Institute For Research On Aging Rapamycin analogs showing improved mTORC1 specificity
WO2017038925A1 (en) * 2015-09-03 2017-03-09 日本化薬株式会社 Pharmaceutical composition containing rapamycin or derivative thereof
US10683308B2 (en) 2015-09-11 2020-06-16 Navitor Pharmaceuticals, Inc. Rapamycin analogs and uses thereof
CN108926533B (en) * 2017-05-24 2022-03-25 江苏天士力帝益药业有限公司 Tesirolimus liposome and preparation method thereof
UY37900A (en) 2017-09-26 2019-04-30 Novartis Ag NEW DERIVATIVES OF RAPAMYCIN
SG11202012447YA (en) 2018-06-15 2021-01-28 Navitor Pharm Inc Rapamycin analogs and uses thereof
WO2020076738A2 (en) 2018-10-12 2020-04-16 Bellicum Pharmaceuticals, Inc Protein-binding compounds
WO2020128861A1 (en) 2018-12-18 2020-06-25 Novartis Ag Rapamycin derivatives
GB2586764B (en) 2019-01-22 2022-02-09 Aeovian Pharmaceuticals Inc MTORC modulators and uses thereof
IL293549A (en) 2019-12-05 2022-08-01 Anakuria Therapeutics Inc Rapamycin analogs and uses thereof
EP4126229A4 (en) 2020-03-27 2024-04-17 Aeovian Pharmaceuticals, Inc. Mtorc1 modulators and uses thereof
WO2022020522A2 (en) 2020-07-21 2022-01-27 Aeovian Pharmaceuticals, Inc. Mtorc1 modulators and uses thereof
MX2023008634A (en) 2021-01-22 2023-10-10 Janssen Pharmaceutica Nv Rapamycin analogs and uses thereof.

Also Published As

Publication number Publication date
US11702429B2 (en) 2023-07-18
WO2020154447A1 (en) 2020-07-30
EA202191983A1 (en) 2021-12-01
MX2021008777A (en) 2022-01-06
GB202018417D0 (en) 2021-01-06
GB2586113B (en) 2022-02-09
CN116947884A (en) 2023-10-27
CN113766916B (en) 2024-04-05
GB202018418D0 (en) 2021-01-06
KR20240033298A (en) 2024-03-12
JP2023113741A (en) 2023-08-16
CN118184678A (en) 2024-06-14
JP7288540B2 (en) 2023-06-07
AU2020210921B2 (en) 2022-02-03
GB2586764A (en) 2021-03-03
US11230557B2 (en) 2022-01-25
CA3127448C (en) 2024-06-04
KR20220034025A (en) 2022-03-17
US20210008041A1 (en) 2021-01-14
KR102643707B1 (en) 2024-03-04
GB202018342D0 (en) 2021-01-06
JP2022511999A (en) 2022-02-01
EP4272825A3 (en) 2023-12-06
EP3914245A1 (en) 2021-12-01
GB2586427A (en) 2021-02-17
GB2586113A (en) 2021-02-03
JP2022095907A (en) 2022-06-28
GB2586764B (en) 2022-02-09
US20230013344A1 (en) 2023-01-19
CN113766916A (en) 2021-12-07
JP2022137237A (en) 2022-09-21
AU2020210921A1 (en) 2021-09-09
JP7061236B2 (en) 2022-04-27
IL285067A (en) 2021-09-30
JP7108804B2 (en) 2022-07-28
EP3914245A4 (en) 2022-08-24
AU2022209289A1 (en) 2022-08-25
BR112021014479A2 (en) 2021-10-13
EP4272825A2 (en) 2023-11-08
CA3236782A1 (en) 2020-07-30
AU2022202241B1 (en) 2022-04-28
US20210002300A1 (en) 2021-01-07
AU2022209289B2 (en) 2024-01-04
GB2586427B (en) 2022-02-09
CA3127448A1 (en) 2020-07-30
ZA202105847B (en) 2023-05-31
MX2023008859A (en) 2023-08-15
US11021492B2 (en) 2021-06-01
US20230080483A1 (en) 2023-03-16

Similar Documents

Publication Publication Date Title
ZA202209159B (en) Mtorc modulators and uses thereof
PH12019550041A1 (en) Compounds and methods for ido and tdo modulation, and indications therefor
TWD197439S (en) Dial
TWD196764S (en) Ring
MX2021002978A (en) Bicyclic lactams and methods of use thereof.
TWD182271S (en) Ring
TWD202790S (en) Ring
TWD211242S (en) Car headlight set
EP3756415A4 (en) Methods of signaling supplementary activity configuration for lean carrier operation
TWD196754S (en) Dial
MX2022006807A (en) Rapamycin analogs and uses thereof.
MY181850A (en) Isocyanate-free synthesis of carbonate-modified polymers
EP4018566A4 (en) Dynamic modification of sounding procedure configuration
IN2015CH01182A (en)
TWD184636S (en) Ring
TWD199594S (en) Detachable bed rail
MX2021008005A (en) Peptide libraries and methods of use thereof.
EP4051259A4 (en) Methods of treatment using an mtorc1 modulator
TWD201207S (en) Ring
TWD201513S (en) Ring
TWD201511S (en) Ring
TWD208431S (en) Car headlight set
TWD196177S (en) electrolyzed water generator
TWD209817S (en) Headlamp
TWD209945S (en) Headlamp